Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21676260 | 0.85 | EGFR (0.54) | TSHRALOX5GAAALDH1A1ALOX15 | |
| SCHEMBL3058844 | 0.80 | SLC6A12 (0.44) | SLC6A12GAACASP1EGFRTUBB4A | |
| SCHEMBL29922180 | 0.78 | SLC6A12 (0.36) | SLC6A12GAAALDH1A1EGFRRECQL | |
| SCHEMBL29450481 | 0.77 | TUBB4A (0.54) | TSHRGAAALDH1A1CASP1TUBB4A | |
| SCHEMBL424747 | 0.77 | TUBB4A (0.54) | TSHRGAAALDH1A1CASP1TUBB4A | |
| SCHEMBL22207155 | 0.76 | CA12 (0.47) | CD274ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL29686663 | 0.76 | SLC6A12 (0.41) | PDCD1LG2CD274SLC6A12KLKB1KLK1 | |
| SCHEMBL25027560 | 0.75 | AR (0.50) | TSHRGAAALDH1A1ALOX15TP53 | |
| SCHEMBL29363618 | 0.75 | AR (0.50) | TSHRGAAALDH1A1ALOX15TP53 | |
| SCHEMBL28089657 | 0.75 | ADORA2A (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | TSHR 4063/4885PDCD1LG2 2866/4885CD274 3381/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | TSHR 4021/4885PDCD1LG2 2916/4885CD274 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.